Both the classical mIL-6R-mediated signaling pathway and the sIL-6R-mediated IL-6 trans-signaling pathway lead to the activation of the JAK/STAT signaling pathway, a major therapeutic target for immunological diseases including rheumatoid arthritis [38,39]. Here, SOAT1 is linked to rheumatoid arthritis.